[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1106682T1 - Ενωση λακταμης - Google Patents

Ενωση λακταμης

Info

Publication number
CY1106682T1
CY1106682T1 CY20071100848T CY071100848T CY1106682T1 CY 1106682 T1 CY1106682 T1 CY 1106682T1 CY 20071100848 T CY20071100848 T CY 20071100848T CY 071100848 T CY071100848 T CY 071100848T CY 1106682 T1 CY1106682 T1 CY 1106682T1
Authority
CY
Cyprus
Prior art keywords
laktamis
association
methods
methyl
alaninyl
Prior art date
Application number
CY20071100848T
Other languages
English (en)
Inventor
Thomas Mitchell Koenig
James Edmund Audia
David Mitchell
Stacey Leigh Mcdaniel
Lynne Ann Buccilli
Gary Lowell Engel
James Abraham Aikins
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1106682T1 publication Critical patent/CY1106682T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cephalosporin Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει την κρυσταλλική διυδρική (Ν)-((S)-2-υδροξυ-3-μεθυλ-βουτυρυλ)-1-(L-αλανινυλ)-(S)-1-αμινο-3-μεθυλ-4,5,6,7-τετραϋδρο-2Η-3-βενζαζεπιν-2-όνη, συνθέσεις αυτής, και μεθόδους για τη χρησιμοποίηση αυτής, μεθόδους για την παρασκευή αυτής, και μεθόδους για την παρασκευή ενδιάμεσων αυτής.
CY20071100848T 2000-11-17 2007-06-28 Ενωση λακταμης CY1106682T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17
PCT/US2001/027795 WO2002040451A2 (en) 2000-11-17 2001-11-02 Lactam compound

Publications (1)

Publication Number Publication Date
CY1106682T1 true CY1106682T1 (el) 2012-05-23

Family

ID=22944436

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100848T CY1106682T1 (el) 2000-11-17 2007-06-28 Ενωση λακταμης

Country Status (33)

Country Link
US (1) US20040248878A1 (el)
EP (1) EP1353910B1 (el)
JP (1) JP4116431B2 (el)
KR (1) KR20030045194A (el)
CN (2) CN100516047C (el)
AR (1) AR031356A1 (el)
AT (1) ATE362919T1 (el)
AU (2) AU2002224321B2 (el)
BR (1) BR0115424A (el)
CA (1) CA2425497C (el)
CY (1) CY1106682T1 (el)
CZ (1) CZ20031340A3 (el)
DE (1) DE60128587T2 (el)
DK (1) DK1353910T3 (el)
DZ (1) DZ3454A1 (el)
EA (1) EA006919B1 (el)
EC (1) ECSP034598A (el)
ES (1) ES2286162T3 (el)
HR (1) HRP20030385A2 (el)
HU (1) HUP0301862A3 (el)
IL (1) IL155275A0 (el)
MX (1) MXPA03004250A (el)
MY (1) MY141607A (el)
NO (1) NO325217B1 (el)
PE (1) PE20020798A1 (el)
PL (1) PL211018B1 (el)
PT (1) PT1353910E (el)
SK (1) SK287794B6 (el)
SV (1) SV2003000741A (el)
TW (1) TWI235151B (el)
UA (1) UA77165C2 (el)
WO (1) WO2002040451A2 (el)
ZA (1) ZA200303411B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
ES2333008T3 (es) 2002-12-20 2010-02-16 Glaxo Group Limited Derivados de benzo(d)azepina para el tratamiento de trastornos neurologicos.
JP2006516572A (ja) 2003-01-14 2006-07-06 アリーナ ファーマシューティカルズ， インコーポレイテッド 代謝モジュレーターとしての１，２，３−トリ置換アリール誘導体および１，２，３−トリ置換ヘテロアリール誘導体ならびにこれらの誘導体に関連する糖尿病および高血糖のような障害の予防および処置
EP1867636B1 (en) 2005-04-08 2013-06-05 Daiichi Sankyo Company, Limited Pyridylmethylsulfone derivative
WO2007088878A1 (ja) * 2006-01-31 2007-08-09 Api Corporation ベンゾアゼピノン類の製造方法
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
KR101871011B1 (ko) 2010-09-22 2018-06-25 아레나 파마슈티칼스, 인크. Ｇｐｒ１１９ 수용체의 조절제 및 그와 관련된 장애의 치료
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
EP2987496B1 (en) 2013-04-19 2018-08-08 National University Corporation Okayama University Treatment agent for cognitive disorders, induced by amyloid -protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
EP4445956A2 (en) 2015-01-06 2024-10-16 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
JP2023520771A (ja) 2020-03-26 2023-05-19 シージェン インコーポレイテッド 多発性骨髄腫を処置する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028268A2 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS
CA2324474A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AU1569501A (en) * 1999-11-09 2001-06-06 Eli Lilly And Company Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis

Also Published As

Publication number Publication date
KR20030045194A (ko) 2003-06-09
CN100516047C (zh) 2009-07-22
DE60128587T2 (de) 2008-01-31
DE60128587D1 (de) 2007-07-05
EP1353910B1 (en) 2007-05-23
WO2002040451A3 (en) 2003-08-28
EA200300579A1 (ru) 2003-12-25
NO20032215L (no) 2003-07-16
TWI235151B (en) 2005-07-01
PL360991A1 (en) 2004-09-20
PT1353910E (pt) 2007-08-20
BR0115424A (pt) 2003-10-21
DK1353910T3 (da) 2007-09-10
EP1353910A2 (en) 2003-10-22
HUP0301862A3 (en) 2007-09-28
ECSP034598A (es) 2003-06-25
PE20020798A1 (es) 2002-09-06
MY141607A (en) 2010-05-31
DZ3454A1 (fr) 2002-05-23
JP4116431B2 (ja) 2008-07-09
HUP0301862A2 (hu) 2003-09-29
JP2004521084A (ja) 2004-07-15
NO325217B1 (no) 2008-02-25
CA2425497A1 (en) 2002-05-23
UA77165C2 (en) 2006-11-15
HRP20030385A2 (en) 2003-08-31
CN1575282A (zh) 2005-02-02
SK5432003A3 (en) 2004-09-08
ES2286162T3 (es) 2007-12-01
WO2002040451A2 (en) 2002-05-23
MXPA03004250A (es) 2003-09-22
IL155275A0 (en) 2003-11-23
CZ20031340A3 (cs) 2004-06-16
AU2432102A (en) 2002-05-27
PL211018B1 (pl) 2012-03-30
ATE362919T1 (de) 2007-06-15
AR031356A1 (es) 2003-09-17
SK287794B6 (sk) 2011-10-04
EA006919B1 (ru) 2006-04-28
NO20032215D0 (no) 2003-05-15
CA2425497C (en) 2010-08-17
US20040248878A1 (en) 2004-12-09
ZA200303411B (en) 2004-08-02
AU2002224321B2 (en) 2006-10-19
CN101624372A (zh) 2010-01-13
SV2003000741A (es) 2003-01-13

Similar Documents

Publication Publication Date Title
CY1106682T1 (el) Ενωση λακταμης
CY1106366T1 (el) Ενωση λακταμης για την αναστολη της απελευθερωσης ή της συνθεσης βητα-αμυλοειδους πεπτιδιου
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
CY1106467T1 (el) Ελεγχομενη συνθεση ζιπρασιδονης
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
BR9902086A (pt) Formulações farmacêuticas.
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
CY1105387T1 (el) Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου
NO20063254L (no) Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
CY1105137T1 (el) Παραγωγα αμινοκυκλοεξυλ αιθερων και χρησεις τους
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DE60227718D1 (de) Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
CY1105345T1 (el) Φαινυλαλκινια
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
TR199901017A2 (xx) B�cek ilac� terkibi.
ITMI20001695A0 (it) Procedimento per la preparazione di composizioni organico-sili-coniche.
CY1106712T1 (el) Υποκατεστημενα παραγωγα 5-αμινο-1-πεντεν-3-ολης
ATE391489T1 (de) Haarbehandlungszusammensetzungen
DE60222806D1 (de) Verfahren zur herstellung von (1,4,5)-oxadiazepinderivaten
DK1328275T3 (da) Substituerede 4,5-dihydro-1,2,4-triazin-3-oner, 1,2,4-triazin-3-oner og deres anvendelse som fungicider og insekticider
ATE545434T1 (de) Stabilisierte zusammensetzungen
CY1105363T1 (el) Ν,ν΄-διυποκατεστημενες ενωσεις πιπepαζινης και η χρηση τους σαν αναλγητικα μεσα
CY1110737T1 (el) Υποκατεστημενες ενωσεις 1,5-διαμινοπενταν-3-ολης